JAB-23E73 — Investigational Agent
KRAS Inhibitor · Phase 1/2 · Jacobio Pharmaceuticals
Mechanism of Action
Selective KRAS G12D inhibitor targeting the most prevalent non-G12C KRAS mutation; binds mutant KRAS G12D to block downstream RAS-MAPK signaling in KRAS G12D-altered tumors.
Investigational Indications
- KRAS G12D-mutant NSCLC
- KRAS G12D-mutant pancreatic and colorectal cancers
- KRAS G12D-altered solid tumors